Ivermectin Medical Valley

Ivermectin, the active ingredient in Ivermectin Medical Valley, is an antiparasitic presented as an oral dosage form for oral use. It treats a range of helminthic and ectoparasitic infections in humans, including river blindness, strongyloidiasis, filariasis, scabies and lice.

GNH USA supplies Ivermectin Medical Valley as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for each batch. Global logistics are coordinated to ensure timely delivery across diverse markets.

Ivermectin is an antiparasitic agent that targets nematodes and ectoparasites, providing therapeutic benefit in several parasitic disease categories. - Onchocerciasis: reduces microfilarial load and helps prevent ocular and skin manifestations. - Strongyloidiasis: eliminates intestinal larvae and prevents disseminated infection. - Lymphatic filariasis: decreases adult worm burden and reduces transmission risk. - Scabies: eradicates Sarcoptes mites, relieving itching and skin lesions. - Pediculosis: kills lice and nits, controlling infestation. - Other helminthic infections: provides broad‑spectrum activity against various intestinal worms.

Ivermectin may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild stomach upset often occurring shortly after dosing. - Diarrhea: loose stools that resolve without treatment. - Dizziness: transient light‑headedness. - Headache: mild to moderate pain.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Anaphylaxis: acute allergic response requiring immediate medical attention.

When prescribing ivermectin, clinicians should consider several precautionary measures to ensure safe use. - Pregnancy: consult a healthcare professional; safety data are limited. - Breastfeeding: weigh potential benefits against risks to the infant. - Renal impairment: use with caution and monitor renal function. - Drug interactions: review concomitant medications for possible interactions. - Store below 25°C: keep in the original pack, protect from moisture.

Ivermectin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin): may markedly reduce ivermectin plasma levels. - Warfarin: concurrent use may enhance anticoagulant effect and increase bleeding risk. - Other neurotoxic antiparasitics: combined use can increase neurotoxicity.

Moderate Interactions (Monitor Closely): - Macrolide antibiotics (e.g., erythromycin): may raise ivermectin concentrations. - Azole antifungals (e.g., ketoconazole): can increase exposure and risk of side effects. - P‑glycoprotein inhibitors: may modestly elevate drug levels.